[Blood pressure control in hypertensive patients with stable coronary heart disease]. / Contrôle de la pression artérielle chez l'hypertendu coronarien stable.

OBJECTIVE: To evaluate systolic blood pressure (SBP) control in hypertensive patients with a stable coronary heart disease (CHD) in general practice in France. METHODS: A survey was conducted in a sample of 206 general practitionners (GP) representative of the French medical population, in 2003 [LHYCORNE survey]. Each GP had to include 3 hypertensive patients, >18 years old, BP > or = 140/90 mmHg and/or treated for hypertension, and with evidence of CHD documented by myocardial infarction (MI) or angina pectoris (AP) [diagnosis previously established by a cardiologist]. Three office BP measurements were performed, the last two recorded. BP levels were considered as controlled by treatement if they were < 140/90 mmHg. RESULTS: 595 patients were included, 75% men mean age 66 years, 25% women mean age 73 years. All patients had a CHD: MI 46%, AP 54%; 533 (90%) had more than 2 cardiovascular risk factors: hyperlipidemia (411; 69%), smokers (375; 63%), diabetes (158; 27%). Mean BP was 140.7 +/- 14/80.8 +/- 9.7 mmHg; 553 (93%) of these hypertensive patients were treated, and 239 (40%) were considered as having a controlled SBP at the treshold of 140 mmHg: 47% in patients with previous MI and 38% with AP (p < 0.001). Diastolic BP (DBP) was <90 mmHg in 480 (81%) and pulse pressure was >65 mmHg in 202 (34%); 313 (53%) patients received a combination of three drugs or more; 354 (60%) had a beta-blocker, 260 (44%) a calcium channel blocker, 237 (40%) an ACE inhibitor, 287 (48%) other antihypertensive drugs (246 diuretics, 41%); 502 (84%) received antiplatelet therapy, 403 (68%) statins. CONCLUSION: This survey shows that systolic BP is not at goal in 6/10 hypertensive patients with stable CHD suggesting there is a place for a more effective combination therapy according to evidence-based medicine.

[Treatment decision as a function of cardiovascular risk in isolated systolic hypertension in general medicine. The PREHSI study]. / Décision thérapeutique en fonction du risque cardiovasculaire dans l'HTA systolique isolée en médecine générale. Etude PREHSI.

OBJECTIVE: To analyse the decision of treatment made by the GP, based on the characteristics of patients with isolated systolic hypertension (ISH). METHODS: 11,436 patients with SBP > or = 140 and DBP < 90 mmHg were examined by 1,464 GPs who filled out a questionnaire for each patient, which included the patient's BP, risk factors, the presence of target organ damage (TOD), antihypertensive treatment and the physician's decision of treatment during the visit. Before the visit, 4,378 patients were not treated: 57 +/- 13 years: 53% men: BP: 157/81 mmHg; smokers: 30%; diabetes: 8%; dyslipidemia: 17%; BMI > 25 kg/m2: 54%; TOD: 11%. Thus, according to ISH tables, 15% of the patients who were not treated presented a low cardiovascular risk (LR), 69% a medium risk (MR), and 16% a high risk (HR). After the visit, 2,599 patients (59%) started antihypertensive treatment. [table: see text] CONCLUSION: 78% of the patients with ISH had at least one other risk factor. Three elements (the grade of ISH, the number of risk factors and the level of CV risks) are significantly taken into account in making the decision of treatment. Decision of treatment was in accordance with ISH recommendation in 91% of patients. Nevertheless, while ISH recommendations are life style measures, only when a LR exists, 39% with a LR were treated. On the other hand, 24% with a HR were not treated.

[Characteristics of patients with isolated systolic hypertension in relation to body mass index. The PREHSI study]. / Caractéristiques des patients avec une HTA systolique isolée en fonction de la masse corporelle. Etude PREHSI.

OBJECTIVE: To analyse patient's isolated systolic hypertension (ISH) in relation to the body mass index (BMI). METHODS: 11,436 patients with SBP > or = 140 and DBP < 90 mmHg were examined by 1,464 GPs who filled in a questionnaire for each patient: the patient's BP, risk factors, the presence of target organ damage (TOD) and antihypertensive treatment. 11,100 patients were split into 3 groups depending on their BMI: Gp 1 (BMI < 25 kg/m2: 4,324), 39%; 62 +/- 14 yrs; 44% men; BP: 157/80 mmHg, 55% treated; Gp 2 (BMI 25 and 30 kg/m2: 5,164) 47%; 62 +/- 12 yrs; 61% men; BP: 158/81 mmHg, 63% treated; and Gp 3 (BMI > 30 kg/m2: 1,612) 14%; 62 +/- 12 yrs; 49% men; BP: 159/81 mmHg, 75% treated. 11,085 patients' CV risks were analysed and categorised into high (HR), medium (MR) and low risk (LR). [table: see text] 11,100 patients' CV history (CVH) were analysed: > 1 CVH were 1,056 (24%) into Gp 1; 1,531 (30%) into Gp 2 and 653 (41%) into Gp 3; left ventricular hypertrophy was 454 (10%) into Gp1; 815 (16%) into Gp 2 and 388 (24%) into Gp 3. CONCLUSION: 61% patients with ISH carry excess weight and 14% are obese. In spite of a more frequent antihypertensive treatment which gives comparable BP levels, the higher the BMI, the higher the CV risk and CV history. Treatment of all CV risks is therefore necessary.

[Registry of heart failure patients hospitalized in 2000. Data from the National College of Cardiology and General Hospital]. / Registre des insufisants cardiaques hospitalisés en 2000. Données du Collége national des cardiologues des hôpitaux généraux (CNCHG).

The French epidemiological data on cardiac insufficiency in the hospital environment are scarce. A register collecting 1772 patients was produced by the services of the National College of General Hospital Cardiologists (C.N.C.H.G.) during two periods: autumn 1999 (November) and spring 2000 (June). It involved completing a form for each of the first 20 patients with cardiac failure hospitalized over a month. 1011 and 761 observations from 59 and 47 centres (that is 17 and 16 observations per centre) were collected during the autumn and spring periods respectively. In France, in the general hospital centres (CHG) cardiology services during the year 2000, the characteristics and the medical treatment of hospitalized patients with cardiac failure are very similar to those presented in 1998 by A. Cohen-Solal in the name of the working group "Cardiomyopathy and Cardiac Insuficiency of the French Society of Cardiology". The hospitalized patient with cardiac failure is very old, usually male, has an ischaemic cardiopathy in one in two cases, and is at stage II and III on the New York Heart Association (NYHA) scale in 83% of cases. There is practically always an electrocardiographic anomaly. Loop diuretics are prescribed nine times out of ten, digitalis one in three, anagiotensin converting enzyme inhibitors are underused being prescribed two out of three times, but an increase in the prescription of anti-aldosterone and betablockers is found. The majority of patients improve during their stay, 7.8% dying and this mortality is influenced by age, ejection fraction (FE), functional NYHA class, causal cardiopathy, and the existence of severe renal failure. The data collected by the cardiology services of the C.N.C.H.G. are representative of the profile of the population affected and are important to know in order to improve the management of these patients.

[Regional management of arterial hypertension in France. Report of a survey of general practitioners]. / Données régionales sur la prise en charge de l'hypertension artérielle en France. A propos de l'enquête PHARE menée en médecine générale.

A survey was conducted in 14 regional samples of general practitioners (GPs) included in Gallup-up poll. 2,423 GPs contributed to the study and had to include all patients > 18 years old over a period of one week. Patients were considered hypertensives if the mean of two recorded BP measurements was > or = 140/90 mmHg and/or < 140/90 mmHg if they were under antihypertensive treatment. Hypertensives were considered as controlled if there BP levels were overall < 140/90 mmHg under treatment. The risk factors associated with hypertension were collected in order to evaluate the cardiovascular risk, according to 1999 ISH-OMS recommendations. 156,470 patients recruited by 2423 GPs were included in the study representing 14 different French regions: Ile-de-France I (1), Ile-de-France II (2), Ile-de-France-Pays-de-la-Loire (3), Bretagne (4), Normandie-Picardie (5), Nord-Pas-de-Calais (6), Alsace-Lorraine (7), Bourgogne-Franche Comté (8), Rhônes-Alpes (9), Provence-Côte d'Azur (10), Languedoc-Provence (11), Limousin-Auvergne (12), Midi-Pyrénées (13), Aquitaine (14). Among 70,073 hypertensives, 23,054 had never received antihypertensive treatment, and 32,059 (47%) had a high or a very high cardiovascular risk. 67% of hypertensives (47,019) were treated, and 32.8% of treated hypertensives (15,422) had a BP < 140/90 mmHg. The study illustrated few differences in prevalence and control of hypertension in the different French regions: BP control at the 140/90 mmHg threshold vary from 28.5 to 36.6% among treated hypertensives and % of patients at high cardiovascular risk from 42.1% (South-France) to 49.7% (East-France).

[Aterial hypertension and cardiovascular risk factors associated with diabetes. Report of the PHARE survey in general practice]. / Hypertension artérielle et facteurs de risque cardiovasculaires associés chez les diabétiques. A propos de l'enquête PHARE menée en médecine générale.

OBJECTIVE: To evaluate the characteristics of diabetic hypertensive patients (Pts), in term of associated cardiovascular risk factors and blood pressure control in a representative population issued from a survey "PHARE" conducted in general practice in France in 1999. DESIGN AND METHODS: PHARE survey was conducted in a sample of 225 GPs representative of the French medical population included in a gallup poll. GPs had to include all patients > 18 years old over a period of one week. Pts were considered as hypertensives (HP) if the mean of two recorded BP measurements was = 140/90 mmHg and/or < 140/90 mmHg if they were under antihypertensive treatment. Patients were considered as diabetics if they were previously known and/or if they received a medication for diabetes. Hypertensives were considered as controlled if their BP levels were overall < 140/90 mmHg or at the recommended threshold < 130/85 mmHg under treatment. RESULTS: 877 diabetic Pts (7%) among 12.342 Pts and 5.190 HP were included in the study. When compared to normotensives, diabetic HP had more frequently associated risk factors with hypertension and diabetes: overweight 71% vs 45%, dyslipidemia 61% vs 34%, sendentarily 73% vs 63%, tobacco consumption 27% vs 20%. The BP control at 140/90 mmHg threshold among treated diabetic HP was 21%, and only 8% at 130/85 mmHg. Regarding WHO classification, 79% of these diabetics had a high or very high cardiovascular risk. The were no difference in antihypertensive drugs used in HP diabetics and non diabetics and 50% of them received ACEI. CONCLUSIONS: 8 from 10 diabetics taken in charge in general practice are hypertensives and 8 from 10 have a very high cardiovascular risk due to a poor BP control and associated cardiovascular risk factors.

[Registry of cardiac insufficiency in cardiology]. / Registre de l'insuffisance cardiaque en cardiologie libérale.

The epidemiological data on cardiac insufficiency in cardiology are very scarce. Therefore, with its members the National College of French Cardiologists has conducted a survey in order to evaluate the clinical, biological and therapeutic characteristics of cardiac insufficiency patients, and thus the possible seasonal variations, and to compare them to the current recommendations and to the data from a previous survey with the same methodology performed in 1994. During each season of the year 622 cardiologists recruited the first 5 cardiac insufficiency patients who had been stable for at least three months. 8618 observations were analysed. The results showed 68% are male with an average age of 70 years, with an ischaemic aetiology in 47% of cases, hypertensive in 23%, and in NYHA stage II or III in 94% of cases. The left ventricular ejection fractions are < 30% in 22% of cases, between 30 and 50% in 62% of cases, and > or = 50% in 16% of cases (20% in those over 78 years). Medical treatment includes diuretics in 78% of cases, with 28% of patients on spironolactone, angiotensin converting enzyme inhibitors (ACE inhibitors) in 82% of cases, betablockers in 29% of cases; ACE inhibitors and betablockers are clearly prescribed more often than during the previous 1994 survey but at doses often lower than the recommendations. Lastly, there are no seasonal variations in prescriptions.

Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists.

An open randomized hospital study conducted in 169 centers in France compared the blood pressure response to the first 36 h of treatment with perindopril (PER), 2 mg once daily, with that to captopril (CAP), 6.25 mg t.i.d., in 725 patients (mean age, 70 years; men, 67%) with echocardiographic left ventricular systolic dysfunction (fractional shortening, < or = 28%) due to ischemia (56.7%) or hypertension (34.5%) and a systolic blood pressure (SBP) > or = 120 mm Hg. Each dose of CAP induced a sharp and rapid decrease in blood pressure (maximum, 1.5-2 h); with PER, the decrease was gradual (maximum, 6 h) and variation was less marked. However, at 36 h, the decrease in blood pressure versus baseline was similar on both treatments. Over the 36-h period, there were 22 (3%) dropouts due to marked orthostatic hypotension (SBP, <90 mm Hg), and they were fewer with PER than with CAP: 16 cases in the CAP group versus six in the PER group (p = 0.036). At 36 h, heart rate was lower with CAP than with PER: 75.2 versus 77.5 beats/min, respectively (p = 0.039). As initial therapy for stabilized left ventricular systolic dysfunction, the first dose of PER (2 mg) induced a significantly smaller decrease in blood pressure than the first dose of CAP (6.25 mg); dropouts due to orthostatic hypotension were also significantly fewer with PER than with CAP.

[New requirements in the primary treatment of arterial hypertension: why do we need fixed low-dose combination therapy?]. / De nouvelles exigences dans le traitement de première intention de l'HTA: pourquoi l'arrivée des plurithérapies fixes microdosées?

The latest results of studies and therapeutic trials have shown the following: Present therapeutic strategies for arterial hypertension have a certain efficacy, but appear to have reached a plateau. Arterial hypertension essentially affects older subjects who can benefit from the advantages of antihypertensive treatment as much as, if not more than, younger subjects. A better evaluation of the cardiovascular risk of the patient is essential: This should include all the components of arterial hypertension (diastolic and systolic blood pressures and pulse pressure), risk factors, associated pathologies, and target-organ damage. Such an evaluation will help fix therapeutic objectives tailored to individual patientsí needs. The limitations of monotherapy in achieving this objective: They are demonstrated in clinical practise, as well as in large-scale trials. In this context, new strategies based on the first-line use of fixed very-low-dose combination therapies appear to be both useful and promising, as well as being in line with the latest recommendations.

An attempt to improve blood pressure control in the French population: information and outcome awareness at the general practitioner level.

To improve blood pressure (BP) control in general practice, 3122 general practitioners agreed to participate in a result awareness program. A survey carried out 6 months after participating physicians had been informed of the outcome of treatments they had given showed that blood pressure control (cut-off point: BP < 140/90 mm Hg) had not improved. However, using less stringent criteria, a slight improvement in blood pressure control could be observed. Although this improvement was marginal, results are sufficiently encouraging to warrant another study after a new awareness campaign among the medical population.

Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994.

A survey was conducted in a cohort of 235 general practitioners (GP) selected by Sofres Medical who were representative of the French medical population, to measure the percentage of patients with hypertension, treated hypertensives and patients with controlled hypertension. Data were collected over 1 week of office consultation. Practitioners were initially instructed to use the same type of mercury sphygmomanometer, equipped with pneumatic cuffs of different sizes. Three consecutive blood pressure (BP) measurements were made and the last two were recorded. Practitioners had to carry out their own survey over a period of 1 week on all patients > 18 years of age who visited their offices. Patients were considered as hypertensive (HP) if the mean of the two recorded BP measurements was > or = 140/90 mm Hg or if they were taking antihypertensive drug treatment. Three cutoff points were used to define controlled hypertension: < 140/90 mm Hg (overall population of HP), < 160/95 mm Hg (HP < 65 years of age), and < 160/90 mm Hg (HP > or = 65 years of age). Among 12,351 patients (mean age, 48.6 years; women, 58%), 5020 were HP, (41%) of whom 2035 were without treatment (41%) and 2985 were receiving antihypertensive drug treatment (59%). Two hundred-thirty patients (4.6%) remained at high risk with moderate or severe hypertension (BP > or = 180 [systolic] or 105 [diastolic] mm Hg), ie, 1 patient/week/GP. The study confirms the high prevalence of hypertension in general practice and shows that 7 of 10 patients have an acceptable control of their BP (< 160/95 or < 160/90 mm Hg according to age) but only 24% of treated HP achieved the target of a BP level < 140/90 mm Hg, representing 28% of the 18 to 64 year old group and 21% of the elderly group. French GP did not choose an optimal control, and the medical community is waiting for answers to crucial questions, ie, does optimal BP control significantly improve the absolute cardiovascular risk? How far should blood pressure be lowered?

[Prevalence, treatment and control of hypertension in family practice patients in France during 1994]. / Prévalence, traitement et contrôle de l'hypertension artérielle chez les consultants en médecine générale en France en 1994.

The aim of this study was to measure the percentage of patients with hypertension, treated hypertension and controlled hypertension, using data collected over one week by 235 general practitioners well representative of the French medical population and selected by SOFRES Médical. Practitioners had to carry out their own survey over a period of one week on all patients above 18 years of age who visited their office. They were initially instructed to use the same type of mercury sphygmomanometer, equiped with the same pneumatic cuffs of different sizes. Three consecutive blood pressure measurements were effected, the last two were recorded. Patients were considered as hypertensive if the mean of the two recorded BP measurements was > or = 140-90 mmHg, or < 140-90 mmHg under pharmacological treatment. Hypertensive patients were considered as controlled when their blood pressure levels were overall < 140-90 mmHg under treatment. According to age, two other control levels were analysed: blood pressure < 160-95 mmHg before 65 years and blood pressure < 160-90 mmHg at 65 years or more. Among 12,351 patients, 5,020 are hypertensive (4%), 2,985 under pharmacological treatment (59%) and 2,035 without treatment (4%). Among untreated patients, 9% had an hypertension above the borderline values. Before 65 years, 28% had an under treatment blood pressure < 140-90 mmHg and 71% < 160-95 mmHg. Among 65 years or more hypertensive patients, 21% had an under treatment blood pressure < 140-90 mmHg and 60% < 160-90 mmHg. Before 65 years, 25% among patients with a monotherapy remained with a blood pressure > 160-95 mmHg and 34% with a blood pressure > 160-90 mmHg among those of 65 years or more; 230 patients (5%) remained in high risk with a blood pressure > 180-105 mmHg. 176 untreated and 54 despite their treatment. This study carried out in French medical practice yield two main conclusions regarding the management of hypertension: as the prevalence of hypertensive patients is 41%: one patient out of two, high blood pressure has to be a main aim for the medical teaching. Even if a reasonable control of the blood pressure is achieved in most cases, blood pressure got a normal level for 24% only of treated hypertensive patients and too many patients were keeping high risk because they have been not or not enough treated. This study, as a real audit, gives some useful informations to general practitioners in order to improve their scores.

[Evaluation of 3 functional classifications of cardiac insufficiency: a national multicenter study. National College of French Cardiologists]. / Evaluation de trois classifications fonctionnelles de l'insuffisance cardiaque: étude multicentrique nationale. Le Collège National des Cardiologues Français.

The scope of this study is a comparison of three functional classifications: the New York Heart Association classification, the Duke University classification, and the specific activity scale we propose. The NYHA classification is subjective, difficult to reproduce and poorly correlated to the functional capacity measured ergometrically (duration of exercise and/or VO2). A new classification must therefore be proposed. A specific activity scale adapted to our national requirements appears to be the best solution. Our study covered 15 successive days. All patients suffering from congestive heart failure who were examined over this period were included. 700 liberal cardiologists took part in this study. 2353 patients were reviewed, mean age 69 (58% male, 42% female). Heart failure was of an ichaemic origin in 37% of cases, idiopathic in 25% and due to hypertension in 25%. Symptomatology was left sided in most cases. Among NYHA Class IV patients, 75% belonged to Class IV of the specific activity scale (SAS) (23% Class III, 1% Class II), and 88% of the Duke classification (10% Class III, 1% Class II). For NYHA Class III patients, 80% were SAS Class III (5% Class IV, 13% Class II), and only 38% (42% Class IV and 16% Class II) of the Duke classification. Regarding NYHA Class II patients, 74% were SAS Class II (21% Class III and 4% Class I), and 26% of the Duke classification (39% Class I, 29% Class III and 3.6% Class IV). Finally, among NYHA Class I patients, 60% were SAS Class I (34% Class II, 5% Class III), and 74% of the Duke classification (11% Class II and 13% Class III).(ABSTRACT TRUNCATED AT 250 WORDS)

[Course of the left ventricular mass in a population of 893 hypertensive patients. Effects of treatment with perindopril]. / Evolution de la masse ventriculaire gauche dans une population de 893 hypertendus. Effets d'une intervention thérapeutique par le perindopril.

Left ventricular hypertrophy is now recognized to be a major and independent risk factor of mortality and morbidity. Although all classes of antihypertensives are able to reduce left ventricular mass, two recent metaanalyses have shown that ACE inhibitors are the most effective. The antihypertensive efficacy of perindopril in man is accompanied with a significant improvement in the functional properties of large arteries and with a reduction of LVH. This study was designed to assess the course of left ventricular mass by echocardiography in a population of 893 hypertensive patients with moderate left ventricular hypertrophy, treated with perindopril for 3 months. A significant fall in blood pressure was observed by the 6th week. The morphological and functional echocardiographic parameters on a large population provided more valid statistical results than in a small series. The left ventricular cavity was found to undergo symmetrical remodelling, adapted to the new haemodynamic status. The reduction of the thickness of the wall was in line with the reduction of the size of the ventricular chamber, and left ventricular mass was reduced by 8% (p < 0.001). Systolic function was preserved and diastolic function was improved. In particular, the E/A ratio was increased by 8% (p < 0.001) and the duration of isometric relaxation was decreased by 11 ms (p < 0.02). This improvement of filling was confirmed by the reduction of the diameter of the left atrium by 0.2 mm (p < 0.001). This open study in 893 patients therefore confirmed that perindopril corrects LVH in hypertensive patients.

[Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice]. / Activité antihypertensive, acceptabilité clinique et biologique du perindopril: principaux resultats chez 23,460 hypertendus légers à modérés traités pendant 6 mois en médecine générale.

Efficacy and acceptability of perindopril (Coversyl) in general practice were evaluated in 23,460 hypertensive patients (52.9% women) during an open six month trial. Patients had essential mild to moderate hypertension (94 mmHg < supine DBP < 115 mmHg) associated or not with obesity (34%), diabetes (12%), hypercholesterolemia (36%), smoking habits (24%). Mean hypertension duration was 6.5 years, 70 p. cent of patients were 50 to 69 years old and 12 p. cent 70 years old or more. Perindopril was started at 4 mg except in older and patients with renal insufficiency (2 mg). If supine DBP remained > 90 mmHg the dose was doubled up to 8 mg/day, then a thiazide diuretic was added. Monotherapy was held in 90 p. cent of cases all along the study, more than 8 over 10 times at 2 or 4 mg/day. Normalized patients (DBP < or = 90 mmHg) were 69.87 and 95 p. cent respectively at the first, third and sixth month. Mean supine SBP and DBP decrease were 27.3 and 18.0 mmHg. Antihypertensive activity was similar in patients taking psychotrope or non steroidal anti-inflammatory agents and in others, as well as in older (> or = 70 years), diabetics and obeses, however with a significantly more frequent bitherapy in these last three sub-groups. Cough, a well known side effect of ACEI led to withdrawal in only 2.6 p. cent of cases. Withdrawals for side-effect were more frequent in older patients (6.1%), in those taking psychotrope (5.3%) or non steroidal anti-inflammatory agents (6.0%) than in diabetics (4.1%) or the others (4.1%).(ABSTRACT TRUNCATED AT 250 WORDS)

[Extramembranous glomerulonephritis induced by lithium]. / Glomérulonéphrite extramembraneuse induite par le lithium.

We report the case of a patient who developed a nephrotic syndrome after lithium carbonate therapy. The nephrotic syndrome disappeared after withdrawal of therapy and recurred when the patient was rechallenged with the same drug. This seems a convincing argument to believe that lithium was the causal agent. Renal biopsy specimens showed membranous nephropathy, suggesting that immune-complex formation was involved in the reaction to the drug. Membranous nephropathy is an exceptional and benign hazard during lithium therapy, and underlines the need for periodic urinalysis in patients treated with the drug.